AOD-9604 Peptide Before and After: What Published Research Documents

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), spanning amino acids 177–191, with an added tyrosine residue at its N-terminus. That structural modification distinguishes it from the unmodified hGH fragment 176–191 — literature on the unmodified fragment is not interchangeable with AOD-9604 data. Early research framed the compound as a candidate for isolating the lipolytic activity of hGH while avoiding hGH's insulin-desensitizing effects. It has since appeared in obesity research, osteoarthritis models, and anti-doping science.

---

What Is AOD-9604 Studied For?

Research on AOD-9604 goes back to 2001 — nearly 25 years — with studies continuing through 2016.

1. Fat Metabolism and Body Weight Reduction — A 2001 preclinical study in obese Zucker rats reported that oral AOD-9604 at 500 µg/kg for 19 days reduced body weight gain by more than 50% compared to untreated controls, accompanied by changes in adipose tissue metabolism (PMID: 11146367).

2. Fat Oxidation and Energy Expenditure — A 2001 preclinical study in obese (ob/ob) and lean C57BL/6J mice found that chronic AOD-9604 treatment increased fat oxidation rates and reduced body weight, with in vitro work in the same study confirming the compound does not activate the hGH receptor (PMID: 11673763).

3. Beta-Adrenergic Pathway Interaction — A 2001 preclinical study in obese mice and beta(3)-adrenergic receptor knockout mice found that both hGH and AOD-9604 influence lipid metabolism through the beta-adrenergic pathway, and that the lipolytic effect was attenuated — though not eliminated — in knockout animals (PMID: 11713213).

4. Osteoarthritis Joint Pathology — A preclinical study in 32 New Zealand white rabbits with collagenase-induced knee osteoarthritis found that intra-articular AOD-9604 injection, both alone and in combination with hyaluronic acid, reduced cartilage degeneration scores compared to saline controls, with the combination group showing the most favorable histological outcomes (PMID: 26275694).

5. Human Clinical Development — A 2005 summary of clinical trial activity documented AOD-9604 progressing into human trials for obesity; as noted in the human research section below, those trials produced results that did not clearly separate from placebo in weight-loss endpoints (PMID: 15834452).

---

How Does AOD-9604 Work?

AOD-9604 is studied as a functional analog of hGH's lipolytic domain. A 2001 rodent study reported that it stimulates lipolysis in adipose tissue and inhibits lipogenesis — the conversion of non-fat food into stored fat — at the tissue level (PMID: 11146367). Critically, in vitro assays in a separate 2001 study confirmed that AOD-9604 does not bind the hGH receptor, which researchers interpreted as evidence that its metabolic effects operate through a distinct, hGH-receptor-independent pathway (PMID: 11673763).

The beta-adrenergic pathway appears to be one candidate mechanism. A 2001 study using beta(3)-adrenergic receptor knockout mice found that removing this receptor blunted but did not abolish the compound's effects on lipid metabolism, suggesting partial — not exclusive — dependence on beta(3)-AR signaling (PMID: 11713213). No human mechanistic data from the primary study pool clarifies whether these rodent-derived pathway findings hold in human physiology.

---

What Does Animal Research on AOD-9604 Show?

Three preclinical studies published in 2001 form the core of the animal evidence base. All used murine models of obesity, and their findings consistently pointed toward lipolytic activity.

The Zucker rat study (PMID: 11146367) reported the most dramatic weight figures: oral dosing over 19 days cut weight gain by more than half relative to controls. Treated animals showed elevated beta-3 adrenergic receptor expression in adipose tissue, which the researchers cited as a potential contributor to the metabolic shift.

The ob/ob mouse study (PMID: 11673763) extended this picture by measuring substrate oxidation directly, finding that fat oxidation increased without a corresponding rise in lean mass catabolism. That same study's in vitro component tested whether the compound triggers hGH-receptor-mediated cell proliferation — it did not, which the authors used to argue against hGH-like mitogenic risk.

The knockout mouse study (PMID: 11713213) compared AOD-9604 and full-length hGH in animals lacking the beta(3)-adrenergic receptor. Both compounds still produced some lipid metabolism changes in knockout animals, indicating that beta(3)-AR is a contributing — not sole — effector in this pathway. The persistence of partial effects in receptor-absent animals left the full mechanism unresolved.

A later rabbit study (PMID: 26275694) moved outside metabolism entirely. In 32 New Zealand white rabbits with surgically induced knee osteoarthritis, weekly intra-articular injections of AOD-9604 produced histologically measurable reductions in cartilage degeneration. Adding hyaluronic acid to the injection further improved scores. The study did not include a pharmacokinetic component and did not clarify why a lipolytic peptide would affect cartilage — a question the authors acknowledged as open.

---

What Does Human Research on AOD-9604 Show?

Human data on AOD-9604 is limited in both volume and outcome strength. A 2005 clinical trial registry summary documented the compound's progression into human obesity trials (PMID: 15834452). Those trials tested AOD-9604 in participants with obesity, and the weight-loss results did not clearly exceed placebo — a finding that contrasts sharply with the magnitude of effects reported in rodent models.

The human data pool in this article clusters around a small number of research groups. Author Ng F M appears in three of the eight primary studies; author Thevis Mario appears in two, both of which involve detection methodology rather than efficacy outcomes. That concentration should be factored into how broadly the findings generalize.

Beyond efficacy trials, two observational studies (PMID: 25208511; PMID: 26578461) examined AOD-9604 from an anti-doping perspective — specifically, how to detect it in urine samples. A 2015 study developed an in vitro metabolic profile of the compound to aid doping control laboratories in identifying it after administration, using human urine specimens (PMID: 25208511). A 2016 study refined urinary detection methods using direct injection liquid chromatography and ion mobility mass spectrometry, with AOD-9604 among the target peptides (PMID: 26578461). These studies confirm that AOD-9604 is detectable in human biological specimens and is classified as a prohibited substance under the World Anti-Doping Agency list — but they were not designed to measure therapeutic outcomes.

A 2015 review of peptidic drugs in sports doping science (PMID: 25382550) noted AOD-9604 among compounds of anti-doping interest precisely because its claimed mechanism — lipolytic activity without hGH receptor binding — makes it attractive as a potential performance aid. That review did not present new human efficacy data.

---

What Is Still Unknown About AOD-9604?

The gap between rodent results and human trial outcomes is the central unresolved problem in AOD-9604 research. Animal studies — conducted entirely in obese murine models — reported robust reductions in fat mass and weight gain. Human trials, as documented in the 2005 clinical registry summary (PMID: 15834452), did not replicate that magnitude of effect. Whether that discrepancy reflects species differences in beta-adrenergic signaling, inadequate trial design, dosing translation failures, or a genuine ceiling on human efficacy is not answered by the current study pool.

The rabbit osteoarthritis findings (PMID: 26275694) raise a separate set of unanswered questions. The biological rationale for a lipolytic peptide affecting joint cartilage is not established in the primary literature reviewed here. No human data on intra-articular use exists in this pool, and the sample size of 32 rabbits across four groups limits statistical confidence.

No long-term safety data in humans is available from the primary studies examined here. The anti-doping detection work confirms human urinary excretion and metabolite profiles, but detection methodology is not a proxy for safety characterization. Research published after 2016 is not represented in this article's primary study pool.

---

Where Can I Buy AOD-9604?

AOD-9604 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---

---